These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 29234249)

  • 21. Targeting CDK4/6 in patients with cancer.
    Hamilton E; Infante JR
    Cancer Treat Rev; 2016 Apr; 45():129-38. PubMed ID: 27017286
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
    Cersosimo RJ
    Am J Health Syst Pharm; 2019 Aug; 76(16):1183-1202. PubMed ID: 31369120
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
    Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM
    Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetic drug evaluation of ribociclib for the treatment of metastatic, hormone-positive breast cancer.
    Curigliano G; Criscitiello C; Esposito A; Intra M; Minucci S
    Expert Opin Drug Metab Toxicol; 2017 May; 13(5):575-581. PubMed ID: 28395543
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advances in pharmacotherapies that target the cell cycle for treatment of breast cancer: where are we at today?
    Perrone M; Giuliani F; Sanna V; Bruno S; Melaccio A; Santoro AN; Laface C; Maselli FM; Iaia ML; Guarini C; Fancellu A; Fedele P
    Expert Opin Pharmacother; 2023 Jun; 24(8):887-900. PubMed ID: 37038927
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer.
    Sobhani N; D'Angelo A; Pittacolo M; Roviello G; Miccoli A; Corona SP; Bernocchi O; Generali D; Otto T
    Cells; 2019 Apr; 8(4):. PubMed ID: 30959874
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Overcoming Endocrine Resistance in Hormone-Receptor Positive Advanced Breast Cancer-The Emerging Role of CDK4/6 Inhibitors.
    O'Sullivan CC
    Int J Cancer Clin Res; 2015; 2(4):. PubMed ID: 26726315
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cyclin-Dependent Kinase 4/6 Inhibitors in Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer.
    Rossi L; McCartney A; Risi E; De Santo I; Migliaccio I; Malorni L; Biganzoli L; Di Leo A
    Clin Breast Cancer; 2019 Dec; 19(6):392-398. PubMed ID: 31358432
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Central nervous system-specific efficacy of CDK4/6 inhibitors in randomized controlled trials for metastatic breast cancer.
    Nguyen LV; Searle K; Jerzak KJ
    Oncotarget; 2019 Oct; 10(59):6317-6322. PubMed ID: 31695840
    [No Abstract]   [Full Text] [Related]  

  • 30. Cyclin-Dependent Kinases 4/6 Inhibitors in Breast Cancer: Current Status, Resistance, and Combination Strategies.
    Niu Y; Xu J; Sun T
    J Cancer; 2019; 10(22):5504-5517. PubMed ID: 31632494
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CDK4/6 Inhibitors in Hormone Receptor-Positive Metastatic Breast Cancer: Current Practice and Knowledge.
    de Melo Gagliato D; C Buzaid A; Perez-Garcia JM; Llombart A; Cortes J
    Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32882980
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emerging data and future directions for CDK4/6 inhibitor treatment of patients with hormone receptor positive HER2-non-amplified metastatic breast cancer.
    Lim E; Beith J; Boyle F; de Boer R; Hui R; McCarthy N; Redfern A; Wade T; Woodward N
    Asia Pac J Clin Oncol; 2018 Oct; 14 Suppl 4():12-21. PubMed ID: 30288929
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetic drug evaluation of palbociclib for the treatment of breast cancer.
    De Luca A; Maiello MR; D'Alessio A; Frezzetti D; Gallo M; Carotenuto M; Normanno N
    Expert Opin Drug Metab Toxicol; 2018 Sep; 14(9):891-900. PubMed ID: 30130984
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm.
    Boyle F; Beith J; Burslem K; de Boer R; Hui R; Lim E; McCarthy N; Redfern A; Woodward N
    Asia Pac J Clin Oncol; 2018 Oct; 14 Suppl 4():3-11. PubMed ID: 30288930
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recent advances of cyclin-dependent kinases as potential therapeutic targets in HR+/HER2- metastatic breast cancer: a focus on ribociclib.
    Edessa D; Sisay M
    Breast Cancer (Dove Med Press); 2017; 9():567-579. PubMed ID: 29263697
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Latest Overview of the Cyclin-Dependent Kinases 4/6 Inhibitors in Breast Cancer: The Past, the Present and the Future.
    Chen X; Xu D; Li X; Zhang J; Xu W; Hou J; Zhang W; Tang J
    J Cancer; 2019; 10(26):6608-6617. PubMed ID: 31777590
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potential biomarkers of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer.
    Fang H; Huang D; Yang F; Guan X
    Breast Cancer Res Treat; 2018 Apr; 168(2):287-297. PubMed ID: 29236235
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
    Giuliano M; Schettini F; Rognoni C; Milani M; Jerusalem G; Bachelot T; De Laurentiis M; Thomas G; De Placido P; Arpino G; De Placido S; Cristofanilli M; Giordano A; Puglisi F; Pistilli B; Prat A; Del Mastro L; Venturini S; Generali D
    Lancet Oncol; 2019 Oct; 20(10):1360-1369. PubMed ID: 31494037
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients.
    Del Re M; Bertolini I; Crucitta S; Fontanelli L; Rofi E; De Angelis C; Diodati L; Cavallero D; Gianfilippo G; Salvadori B; Fogli S; Falcone A; Scatena C; Naccarato AG; Roncella M; Ghilli M; Morganti R; Fontana A; Danesi R
    Breast Cancer Res Treat; 2019 Nov; 178(1):57-62. PubMed ID: 31346846
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanisms of therapeutic CDK4/6 inhibition in breast cancer.
    Scott SC; Lee SS; Abraham J
    Semin Oncol; 2017 Dec; 44(6):385-394. PubMed ID: 29935900
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.